A Short Communication on Sweeteners and their Relative Profiles

2021 ◽  
Vol 3 (2) ◽  
Author(s):  
Avisek Dutta ◽  
Avisek Dutta
Keyword(s):  
Oxidative Stress ◽  
Blood Pressure ◽  
Short Communication ◽  
Artificial Sweeteners ◽  
Diabetic Patients ◽  
Central Adiposity ◽  
Sugar Intake ◽  
Cane Juice ◽  
Sugar Levels

Jaggery has been used traditionally in all Indian villages. It is a concentrated product of cane juice which has 50% sucrose, up to 20% invert sugars, and also contains insoluble matter, such as wood ash, proteins, and fibres, whereas granulated sugar, refers to sucrose, a disaccharide composed of glucose and fructose. Jaggery is better option than sugar in diabetics since it reduces oxidative stress in diabetic patients. Sugar intake on long term causes dysglycemia. Constant raised sugar levels have produces central adiposity, hypertension or some elevation of blood pressure, hyperglycaemic episodes in form of glucose intolerance. Artificial sweeteners on long term usage can be possibly not favourable as they cause weight gain, hypertension. There is no corelation of any tumour production with Aspartame.

scholarly journals Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.

2010 ◽  
Vol 57 (1) ◽  
Author(s):  
Marcin Renke ◽  
Leszek Tylicki ◽  
Przemysław Rutkowski ◽  
Narcyz Knap ◽  
Marcin Zietkiewicz ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Phosphodiesterase Inhibitor ◽  
Diabetic Patients ◽  
Tubular Injury ◽  
Converting Enzyme Inhibitors ◽  
Stress Dependent ◽  
And Oxidative Stress

Inhibition of the renin-angiotensin-aldosterone system (RAAS) with angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II subtype 1 receptor antagonists (ARB) is a common strategy used in the management of patients with chronic kidney disease (CKD). However, there is no universal therapy that can stop progression of CKD. Pentoxifylline (PTE) is a non-specific phosphodiesterase inhibitor with anti-inflammatory properties. It has been reported to have promising effects in CKD treatment. In a placebo-controlled, randomized, cross-over study we evaluated the influence of PTE (1200 mg/day) added to RAAS blockade on proteinuria, surrogate markers of tubular injury and oxidative stress-dependent products in 22 non-diabetic patients with proteinuria (0.4-4.3 g per 24 h) with normal or declined kidney function [eGFR 37-178 mL/min]. In an eight-week run-in period, therapy using ACEI and/or ARB was adjusted to achieve a blood pressure below 130/80 mm Hg. Next, patients were randomly assigned to one of two treatment sequences: PTE/washout/placebo or placebo/washout/PTE. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study. The PTE therapy reduced proteinuria (by 26%) as compared to placebo. There were no differences in alpha(1)-microglobulin, urine excretion of N-acetyl-beta-d-glucosaminidase (NAG), hsCRP, the urinary excretion of 15-F(2)t-isoprostane, blood pressure (BP), eGFR and serum creatinine between the PTE and placebo groups. Pentoxifylline may decrease proteinuria in non-diabetic patients with CKD.

PREVALENCE OF DIABETIC COMPLICATIONS IN AN URBAN DISTRICT OF JHANG (PUNJAB) PAKISTAN

2011 ◽  
Vol 1 ◽  
pp. 43-49
Author(s):  
Muhammad Shoaib Akhtar
Keyword(s):  
Blood Pressure ◽  
Socioeconomic Status ◽  
Diabetic Complications ◽  
Cultural Influences ◽  
Educational Status ◽  
World Health ◽  
Diabetic Patients ◽  
Urban District ◽  
The World ◽  
Sugar Levels

he diabetic complications have become a world health problem. They prevail throughout the world but their percentages differ in different areas due to cultural influences. Therefore, we have determined prevalence of complications of diabetes in the rural population of district Jhang (Pakistan). For this purpose, a performa was developed and information was collected from two hundred and ten (210) diabetic patients about their age, sex, height, socioeconomic status, educational status, type of diabetes, duration of diabetes, age at diagnosis, blood pressure and blood sugar levels ( fasting and random) and the symptoms of diabetes.

Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy

1987 ◽  
Vol 24 (3) ◽  
pp. 229-239 ◽  
Author(s):  
Sebastiano Bruno Solerte ◽  
Marisa Fioravanti ◽  
Anna Linda Patti ◽  
Nicola Schifino ◽  
Maria Grazia Zanoletti ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Excretion Rate ◽  
Urinary Protein Excretion ◽  
Diabetic Patients ◽  
Overt Nephropathy ◽  
Protein Excretion ◽  
Arterial Blood ◽  
Insulin Dependent ◽  
Insulin Dependent Diabetic

scholarly journals Relationship of HbA1c Values to Retinopathy, Nephropathy, and Cardiovascular

2020 ◽  
Vol 10 (01) ◽  
pp. 127-130
Author(s):  
Aaya Hamid Al-Hakeem ◽  
Hadeel Haider Saleh
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Diabetic Retinopathy ◽  
Glycated Hemoglobin ◽  
Microvascular Complications ◽  
Diabetic Patients ◽  
Glycaemia Control ◽  
Relationship Of ◽  
Hba1c Levels

A total of 50 patients aged 35-75 years From Al-Sader educational Hospital in Al-Najaf city was studied to determine the glycated hemoglobin risk factors with value creatinine and urea in serum and diabetic nephropathy. Diabetic patient were (35-45 years old) with HbA1c 7.9 % (60mmol/mol). Patient were (45–55 years old), glycated hemoglobin (HbA1c) andgt; 8.5 %. Patients between (55–65 years were glycated hemoglobin (HbA1c) andgt;10.5 %. HbA1c levels, lipid profile, level of Creatinine and urea in serum, family history, BMI, blood pressure, disease severity, and complications were determined. Most patients developed some grade of retinopathy (examined by an ophthalmologist) except those with HbA1c 6.7% (50mmol/mol). Diabetic patients aged (55–65 years old) with HbA1c 7.6% (60mmol/mol). Patients aged 56–75 years old of glycated hemoglobin (HbA1c) andgt;7% with poor glycaemia control ≥ 126mg/dL were assessed to classify diabetic retinopathy. HbA1c and GA are associated with nephropathy separately. Retinopathy and nephropathy may respond to different aspects of hyperglycemia. The GA found as a powerful indicator of microvascular complications same as HbA1c where long-term glycaemia is the risk factor.

scholarly journals Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats

2011 ◽  
Vol 210 (3) ◽  
pp. 293-308 ◽  
Author(s):  
Victor P Bilan ◽  
Eman M Salah ◽  
Sheldon Bastacky ◽  
Huw B Jones ◽  
Rachel M Mayers ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Diabetic Nephropathy ◽  
Renal Disease ◽  
Chronic Renal Disease ◽  
Diabetic Patients ◽  
High Dose ◽  
Long Term Treatment ◽  
Tubulointerstitial Inflammation

Diabetic nephropathy (DN) is a major cause of end-stage renal disease. Yet the pathogenic mechanisms underlying the development of DN are not fully defined, partially due to lack of suitable models that mimic the complex pathogenesis of renal disease in diabetic patients. In this study, we describe early and late renal manifestations of DN and renal responses to long-term treatments with rosiglitazone or high-dose enalapril in ZSF1 rats, a model of metabolic syndrome, diabetes, and chronic renal disease. At 8 weeks of age, obese ZSF1 rats developed metabolic syndrome and diabetes (hyperglycemia, glucosuria, hyperlipidemia, and hypertension) and early signs of renal disease (proteinuria, glomerular collagen IV deposition, tubulointerstitial inflammation, and renal hypertrophy). By 32 weeks of age, animals developed renal histopathology consistent with DN, including mesangial expansion, glomerulosclerosis, tubulointerstitial inflammation and fibrosis, tubular dilation and atrophy, and arteriolar thickening. Rosiglitazone markedly increased body weight but reduced food intake, improved glucose control, and attenuated hyperlipidemia and liver and kidney injury. In contrast, rosiglitazone markedly increased cardiac hypertrophy via a blood pressure-independent mechanism. High-dose enalapril did not improve glucose homeostasis, but normalized blood pressure, and nearly prevented diabetic renal injury. The ZSF1 model thus detects the clinical observations seen with rosiglitazone and enalapril in terms of primary and secondary endpoints of cardiac and renal effects. This and previous reports indicate that the obese ZSF1 rat meets currently accepted criteria for progressive experimental diabetic renal disease in rodents, suggesting that this may be the best available rat model for simulation of human DN.

Sign in / Sign up

Export Citation Format

Share Document